644 related articles for article (PubMed ID: 23806160)
1. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.
Fett N
Clin Dermatol; 2013; 31(4):432-437. PubMed ID: 23806160
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid for treatment of systemic sclerosis and morphea: A literature review.
Thomas RM; Worswick S; Aleshin M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 28032675
[TBL] [Abstract][Full Text] [Related]
3. Localized scleroderma.
Kreuter A
Dermatol Ther; 2012; 25(2):135-47. PubMed ID: 22741933
[TBL] [Abstract][Full Text] [Related]
4. Morphea and Eosinophilic Fasciitis: An Update.
Mertens JS; Seyger MMB; Thurlings RM; Radstake TRDJ; de Jong EMGJ
Am J Clin Dermatol; 2017 Aug; 18(4):491-512. PubMed ID: 28303481
[TBL] [Abstract][Full Text] [Related]
5. Morphea and localized scleroderma in children.
Vierra E; Cunningham BB
Semin Cutan Med Surg; 1999 Sep; 18(3):210-25. PubMed ID: 10468041
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic and therapeutic problems of scleroderma].
Pogorzelska-Antkowiak A; Antkowiak R
Wiad Lek; 2006; 59(5-6):392-5. PubMed ID: 17017489
[TBL] [Abstract][Full Text] [Related]
7. Morphea: a practical review of its diagnosis, classification and treatment.
Rodríguez-Salgado P; García-Romero MT
Gac Med Mex; 2019; 155(5):483-491. PubMed ID: 32091025
[TBL] [Abstract][Full Text] [Related]
8. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
McGaugh S; Kallis P; De Benedetto A; Thomas RM
Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
[TBL] [Abstract][Full Text] [Related]
10. Upcoming treatments for morphea.
Wenzel D; Haddadi NS; Afshari K; Richmond JM; Rashighi M
Immun Inflamm Dis; 2021 Dec; 9(4):1101-1145. PubMed ID: 34272836
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
Ferreli C; Gasparini G; Parodi A; Cozzani E; Rongioletti F; Atzori L
Clin Rev Allergy Immunol; 2017 Dec; 53(3):306-336. PubMed ID: 28712039
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations of selected rheumatologic diseases.
Ostezan LB; Callen JP
Am Fam Physician; 1996 Apr; 53(5):1625-36. PubMed ID: 8623690
[TBL] [Abstract][Full Text] [Related]
13. Localized and systemic scleroderma.
Hawk A; English JC
Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
[TBL] [Abstract][Full Text] [Related]
14. Update on the classification and treatment of localized scleroderma.
Bielsa Marsol I
Actas Dermosifiliogr; 2013 Oct; 104(8):654-66. PubMed ID: 23948159
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis and localized scleroderma in childhood.
Zulian F
Rheum Dis Clin North Am; 2008 Feb; 34(1):239-55; ix. PubMed ID: 18329543
[TBL] [Abstract][Full Text] [Related]
16. Localized scleroderma: clinical spectrum and therapeutic update.
Careta MF; Romiti R
An Bras Dermatol; 2015; 90(1):62-73. PubMed ID: 25672301
[TBL] [Abstract][Full Text] [Related]
17. [Localized scleroderma (morphea) in childhood].
Weibel L
Hautarzt; 2012 Feb; 63(2):89-96. PubMed ID: 22290277
[TBL] [Abstract][Full Text] [Related]
18. Palindromic morphea: multiple recurrence of morphea lesions in a case of systemic sclerosis.
Mizutani H; Tanaka H; Okada H; Mizutani T; Shimizu M
J Dermatol; 1992 May; 19(5):298-301. PubMed ID: 1644954
[TBL] [Abstract][Full Text] [Related]
19. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma.
Hansen CB; Callen JP
Dermatol Ther; 2010; 23(4):341-9. PubMed ID: 20666821
[TBL] [Abstract][Full Text] [Related]
20. [Localized scleroderma (morphea)].
Bono W; Dupin N
Presse Med; 2006 Dec; 35(12 Pt 2):1923-8. PubMed ID: 17159718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
